新型双环杂环化合物作为治疗炎症性疾病的MRGPRX2拮抗剂
Novel Bicyclic Heterocycles as MRGPRX2 Antagonists for Treating Inflammatory Diseases.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2025 Jun 2;16(6):980-981. doi: 10.1021/acsmedchemlett.5c00305. eCollection 2025 Jun 12.
Abstract
Provided herein are novel bicyclic heterocycles as MRGPRX2 antagonists, pharmaceutical compositions, use of such compounds in treating inflammatory diseases, and processes for preparing such compounds.
摘要
本文提供了作为MRGPRX2拮抗剂的新型双环杂环化合物、药物组合物、此类化合物在治疗炎性疾病中的用途以及制备此类化合物的方法。
相似文献
1
Novel Bicyclic Heterocycles as MRGPRX2 Antagonists for Treating Inflammatory Diseases.新型双环杂环化合物作为治疗炎症性疾病的MRGPRX2拮抗剂
ACS Med Chem Lett. 2025 Jun 2;16(6):980-981. doi: 10.1021/acsmedchemlett.5c00305. eCollection 2025 Jun 12.
2
Novel Bicyclic Heterocycles as MRGPRX2 Antagonists for Treating Inflammatory Diseases.作为治疗炎症性疾病的MRGPRX2拮抗剂的新型双环杂环化合物
ACS Med Chem Lett. 2025 Apr 2;16(5):732-733. doi: 10.1021/acsmedchemlett.5c00165. eCollection 2025 May 8.
3
Novel Bicyclic Heterocyclic Compounds as CD73 Inhibitors for Treating Cancer.作为用于治疗癌症的CD73抑制剂的新型双环杂环化合物。
ACS Med Chem Lett. 2024 Dec 4;16(1):10-11. doi: 10.1021/acsmedchemlett.4c00565. eCollection 2025 Jan 9.
4
Bicyclic Ureas as JAK2 Inhibitors for Treating Hematological Cancer.双环脲类化合物作为治疗血液系统癌症的JAK2抑制剂
ACS Med Chem Lett. 2024 Oct 29;15(11):1824-1825. doi: 10.1021/acsmedchemlett.4c00496. eCollection 2024 Nov 14.
5
Novel Bicyclic Amines as CDK2 Inhibitors for Treating Metastatic Breast Cancer or Metastatic Lung Cancer.新型双环胺类化合物作为治疗转移性乳腺癌或转移性肺癌的细胞周期蛋白依赖性激酶2（CDK2）抑制剂
ACS Med Chem Lett. 2025 Jan 16;16(2):198-199. doi: 10.1021/acsmedchemlett.5c00005. eCollection 2025 Feb 13.
6
Novel Bicyclic DGK Inhibitors for Treating Metastatic Melanoma.用于治疗转移性黑色素瘤的新型双环二酰甘油激酶抑制剂
ACS Med Chem Lett. 2025 Apr 2;16(5):728-729. doi: 10.1021/acsmedchemlett.5c00164. eCollection 2025 May 8.
7
Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.新型色胺化合物作为5-HT2A激动剂用于治疗情绪障碍，如抑郁症和双相情感障碍。
ACS Med Chem Lett. 2025 Feb 13;16(3):373-374. doi: 10.1021/acsmedchemlett.5c00047. eCollection 2025 Mar 13.
8
Novel Ergoline Compounds as 5-HT2A Agonists for Treating Mood Disorders Such as Depressive Disorders and Bipolar Disorders.新型麦角灵化合物作为5-HT2A激动剂用于治疗情绪障碍，如抑郁症和双相情感障碍。
ACS Med Chem Lett. 2024 Dec 20;16(1):32-33. doi: 10.1021/acsmedchemlett.4c00593. eCollection 2025 Jan 9.
9
Novel Imidazotriazine Derivatives as IL-17 Modulators for Treating Inflammatory and Autoimmune Disorders.新型咪唑并三嗪衍生物作为治疗炎症和自身免疫性疾病的白细胞介素-17调节剂
ACS Med Chem Lett. 2024 Dec 10;16(1):12-13. doi: 10.1021/acsmedchemlett.4c00573. eCollection 2025 Jan 9.
10
Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases.作为治疗心血管疾病的NLRP3抑制剂的新型化合物。
ACS Med Chem Lett. 2024 Jul 11;15(8):1184-1185. doi: 10.1021/acsmedchemlett.4c00304. eCollection 2024 Aug 8.
本文引用的文献
1
Novel Bicyclic Heterocycles as MRGPRX2 Antagonists for Treating Inflammatory Diseases.作为治疗炎症性疾病的MRGPRX2拮抗剂的新型双环杂环化合物
ACS Med Chem Lett. 2025 Apr 2;16(5):732-733. doi: 10.1021/acsmedchemlett.5c00165. eCollection 2025 May 8.
2
Mast Cells and Mas-related G Protein-coupled Receptor X2: Itching for Novel Pathophysiological Insights to Clinical Relevance.肥大细胞和 Mas 相关 G 蛋白偶联受体 X2：渴望为临床相关性提供新的病理生理学见解。
Curr Allergy Asthma Rep. 2024 Nov 25;25(1):5. doi: 10.1007/s11882-024-01183-5.
3
Mast cell modulation: A novel therapeutic strategy for abdominal pain in irritable bowel syndrome.肥大细胞调节：肠易激综合征腹痛的一种新的治疗策略。
Cell Rep Med. 2024 Oct 15;5(10):101780. doi: 10.1016/j.xcrm.2024.101780. Epub 2024 Oct 7.
4
The evolving role of mast cells in wound healing: insights from recent research and diverse models.肥大细胞在伤口愈合中的作用演变：来自最新研究和不同模型的见解。
Immunol Cell Biol. 2024 Nov;102(10):878-890. doi: 10.1111/imcb.12824. Epub 2024 Oct 8.
5
The MRGPR family of receptors in immunity.MRGPR 家族受体与免疫
Immunity. 2024 Jan 9;57(1):28-39. doi: 10.1016/j.immuni.2023.12.012.
Zotero 插件